Abstract: A hollow body includes a wall which at least partially surrounds an interior volume of the hollow body. The wall includes a layer of glass and has a wall surface. The wall surface includes a surface region in which the layer of glass is at least partially superimposed by a plurality of particles. The plurality of particles is characterized by a particle size distribution having a D50 in a range from 1 to 100 ?m. A hollow body having a wall surface including a surface region which is characterized by a coefficient of dry sliding friction of less than 0.15 is also provided.

Abstract: An electronic reader may operate in a normal mode. The reader may evaluate criteria to determine whether to continue operating in the normal mode or operate in a secure mode. The secure mode may include deactivating functionality in the reader. Deactivating functionality may include at least one of disabling a credential reading functionality, disabling a credential processing functionality, and disabling a credential communicating functionality.

Abstract: A process for making a functionalized hollow body includes: providing a hollow body including a wall which at least partially surrounds an interior volume of the hollow body, the wall including a layer of glass and having a wall surface with a surface region; at least partially superimposing the layer of glass in the surface region with a functionalizing composition precursor on a side of the layer of glass which faces away from the interior volume, the functionalizing composition precursor including one or more siloxanes; and at least partially contacting the functionalizing composition precursor with a plasma, thereby obtaining the functionalized hollow body including a functionalizing composition which at least partially superimposes the layer of glass in the surface region on the side of the layer of glass which faces away from the interior volume.

Abstract: A glass container includes a hollow body of a glass material. The hollow body surrounds an inner volume and has a lower end and an upper end. A container opening extends through the upper end into the inner volume. The hollow body further includes a container collar surrounding the container opening, a container neck, a container shoulder, a container body, a container bottom closing the lower end, and an inner container surface facing the inner volume and an outer container surface facing away from the inner volume. The glass container is coated on its outer container surface at least partially with a coating and the coated glass container has an increased scratch resistance with respect to a contact of the glass container with at least one further glass container.

Abstract: A method for processing of glass containers includes: simultaneously subjecting the glass containers to a first processing step; and simultaneously subjecting the glass containers to a second processing step after the first processing step. At least one of before or during at least one of the first processing step or the second processing step an outer container surface of each glass container is contact-free or in contact with a material having a lower hardness than that of the glass container or only in contact with such materials.

Abstract: Container precursors are provided that have a wall of glass. The wall of glass at least partially encloses an interior volume. The wall of glass has a side that faces away from the interior volume. The side is at least partially superimposed by a plurality of particles. An arrangement is also provided that includes a packaging and a multitude of the container precursors. A process for preparing a functionalised container precursor is also provided. A process for packaging pharmaceutical compositions and closed containers obtainable by this process are provided.

Abstract: The invention relates to a method for producing a composite material with a decorative coating, wherein a porous layer that includes pigment particles is applied onto a glass or glass ceramic substrate. The porous layer is filled with a polymer.

Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.

Abstract: A hollow body includes a wall which at least partially surrounds an interior volume of the hollow body. The wall includes a layer of glass and has a wall surface. The wall surface includes a surface region in which the layer of glass is at least partially superimposed by a plurality of particles. The plurality of particles is characterized by a particle size distribution having a D50 in a range from 1 to 100 ?m. A hollow body having a wall surface including a surface region which is characterized by a coefficient of dry sliding friction of less than 0.15 is also provided.

Abstract: A process for making a functionalized hollow body includes: providing a hollow body including a wall which at least partially surrounds an interior volume of the hollow body, the wall including a layer of glass and having a wall surface with a surface region; at least partially superimposing the layer of glass in the surface region with a functionalizing composition precursor on a side of the layer of glass which faces away from the interior volume, the functionalizing composition precursor including one or more siloxanes; and at least partially contacting the functionalizing composition precursor with a plasma, thereby obtaining the functionalized hollow body including a functionalizing composition which at least partially superimposes the layer of glass in the surface region on the side of the layer of glass which faces away from the interior volume.

Abstract: A hollow body includes a wall which at least partially surrounds an interior volume of the hollow body. The wall comprises a layer of glass and has a wall surface. The wall surface comprises a surface region which is characterized by a contact angle for wetting with water of at least 80°. A process for making an item; a hollow body obtainable by this process; a closed container; a process for packaging a pharmaceutical composition; a closed hollow body obtainable by this process; a use of one of the hollow bodies; and a use of a perfluorinated silane or a perfluorosulfonic acid or both is also provided.

Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.

Abstract: A display device is provided that is a transparent, colored glass-ceramic with a display face on the front, an illumination face on the back, and at least one light-emitting element being disposed in the region of the illumination face. The display device further includes a color compensation filter in the form of a color layer introduced directly or indirectly on the glass ceramics.

Abstract: A method for producing a sol-gel ink, in particular from TEOS and MTEOS, is provided. The method includes adding inorganic particles as a filler and adding a high-boiling solvent.

Abstract: The invention relates to an expression system comprising a prokaryotic cell which contains a polynucleotide construct that encodes a T7 RNA polymerase under the control of a T7 promoter and under the control of an inducible promoter. The invention also relates to an expression vector which contains a gene that encodes a protein to be expressed under the control of a T7 promoter, characterized in that said expression vector comprises a plasmid stabilization system.

Abstract: A semi-transparent coating material for coating glass or glass ceramics includes at least one sol-gel hybrid-polymer coating system having a hybrid-polymer or inorganic sol-gel-based matrix, and nanoparticles and nanoscale pigments and/or dyes are added to the hybrid-polymer or inorganic sol-gel-based matrix.

Abstract: Disclosed are articles that are provided with a haptically-perceptible surface. The articles include a coated glass or glass ceramic substrate which is provided with a layer with haptic properties so that the layer has a haptically perceptible texture. The layer includes texturing inorganic and/or polysiloxane-based particles which are fixed on the substrate by a layer-forming material. The particles cause protrusions on the layer and so produce the haptically perceptible texture.

Abstract: The invention relates to an expression system comprising a prokaryotic cell which contains a polynucleotide construct that encodes a T7 RNA polymerase under the control of a T7 promoter and under the control of an inducible promoter. The invention also relates to an expression vector which contains a gene that encodes a protein to be expressed under the control of a T7 promoter, characterized in that said expression vector comprises a plasmid stabilization system.

Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.

Abstract: An electronic reader may operate in a normal mode. The reader may evaluate criteria to determine whether to continue operating in the normal mode or operate in a secure mode. The secure mode may include deactivating functionality in the reader. Deactivating functionality may include at least one of disabling a credential reading functionality, disabling a credential processing functionality, and disabling a credential communicating functionality.